Expert review of respiratory medicine最新文献_第10页

Small airways disease in chronic obstructive pulmonary disease. 慢性阻塞性肺病中的小气道疾病。

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-07-24 DOI: 10.1080/17476348.2024.2380070

Nikolaos Lazarinis, Evangelia Fouka, Anders Linden, Apostolos Bossios

{"title":"Small airways disease in chronic obstructive pulmonary disease.","authors":"Nikolaos Lazarinis, Evangelia Fouka, Anders Linden, Apostolos Bossios","doi":"10.1080/17476348.2024.2380070","DOIUrl":"10.1080/17476348.2024.2380070","url":null,"abstract":"Introduction: Small airway disease (SAD) represents a common and critical feature of Chronic Obstructive Pulmonary Disease (COPD). Introduced in the '60s, SAD has gradually gained increasing interest as assessment methodologies have improved. Chronic exposure to smoking and noxious particles or gases induces inflammation and remodeling, leading to airway obstruction and SAD, eventually resulting in complete airway loss.Areas covered: A literature search up to June 2024 was performed in PubMed to identify articles on SAD and airway diseases mainly COPD, but also to the extent that it seemed relevant in the uncontrolled/severe asthma field, where SAD is better studied. We provide clinicians and translational scientists with a comprehensive analysis of the existing literature on SAD in COPD, concentrating on the underlying pathophysiological mechanisms, diagnostic techniques, and current pharmacological approaches targeting airflow obstruction in small airways.Expert opinion: Small airways are the primary site for the onset and progression of airflow obstruction in patients with COPD, with significant clinical consequences associated with poor lung function, hyperinflation, and impaired quality of life. The early identification of individuals with subclinical SAD may allow us to prevent its further progress from airway loss and potential development of emphysema and choose the appropriate therapeutic approach.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"539-552"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical evidence and technical aspects of innovative technology and monitoring of chronic NIV in COPD: a narrative review. 慢性阻塞性肺疾病慢性 NIV 监测创新技术的临床证据和技术方面：叙述性综述。

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-08-13 DOI: 10.1080/17476348.2024.2384024

F Soleimani, D W Donker, E Oppersma, M L Duiverman

{"title":"Clinical evidence and technical aspects of innovative technology and monitoring of chronic NIV in COPD: a narrative review.","authors":"F Soleimani, D W Donker, E Oppersma, M L Duiverman","doi":"10.1080/17476348.2024.2384024","DOIUrl":"10.1080/17476348.2024.2384024","url":null,"abstract":"Introduction: Chronic nocturnal noninvasive ventilation (NIV) improves outcomes in COPD patients with chronic hypercapnic respiratory failure. The aim of chronic NIV in COPD is to control chronic hypercapnic respiratory insufficiency and reduce symptoms of nocturnal hypoventilation, thereby improving quality of life. Chronic NIV care is more and more offered exclusively at home, enabling promising outcomes in terms of patient and caregiver satisfaction, hospital care consumption and cost reduction. Yet, to achieve and maintain optimal ventilation, during adaptation and follow-up, effective feasible (home) monitoring poses a significant challenge.Areas covered: Comprehensive monitoring of COPD patients receiving chronic NIV requires integrating data from ventilators and assessment of the patient's status including gas exchange, sleep quality, and patient-reported outcomes. The present article describes the physiological background of monitoring during NIV and aims to provide an overview of existing methods for monitoring, assessing their reliability and clinical relevance.Expert opinion: Patients on chronic NIV are 'ideal' candidates for home monitoring; the advantages of transforming hospital to home care are huge for patients and caregivers and for healthcare systems facing increasing patient numbers. Despite the multitude of available monitoring methods, identifying and characterizing the most relevant parameters associated with optimal patient well-being remains unclear.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"513-526"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of venous blood gas in assessing arterial acid-base and oxygenation status - an analysis of aggregated data from multiple studies evaluating the venous to arterial conversion (v-TAC) method. 使用静脉血气评估动脉酸碱和氧合状态--对评估静脉到动脉转换（v-TAC）方法的多项研究的汇总数据进行分析。

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-07-15 DOI: 10.1080/17476348.2024.2378021

Lisha Shastri, Lars Pilegaard Thomsen, Marianne Toftegaard, Gitte Boier Tygesen, Ulla Møller Weinreich, Beate Agnieszka Rychwicka-Kielek, Michael Gordon Davies, Magnus Ekström, Harald Rittger, Anne-Maree Kelly, Søren Risom Kristensen, Søren Kjærgaard, Panagiotis Kamperidis, Ari Manuel, Kjeld Asbjørn Damgaard, Steen Andreassen, Stephen Edward Rees

{"title":"The use of venous blood gas in assessing arterial acid-base and oxygenation status - an analysis of aggregated data from multiple studies evaluating the venous to arterial conversion (v-TAC) method.","authors":"Lisha Shastri, Lars Pilegaard Thomsen, Marianne Toftegaard, Gitte Boier Tygesen, Ulla Møller Weinreich, Beate Agnieszka Rychwicka-Kielek, Michael Gordon Davies, Magnus Ekström, Harald Rittger, Anne-Maree Kelly, Søren Risom Kristensen, Søren Kjærgaard, Panagiotis Kamperidis, Ari Manuel, Kjeld Asbjørn Damgaard, Steen Andreassen, Stephen Edward Rees","doi":"10.1080/17476348.2024.2378021","DOIUrl":"10.1080/17476348.2024.2378021","url":null,"abstract":"Background: Several methods exist to reduce the number of arterial blood gases (ABGs). One method, Roche v-TAC, has been evaluated in different patient groups. This paper aggregates data from these studies, in different patient categories using common analysis criteria.Research design and methods: We included studies evaluating v-TAC based on paired arterial and peripheral venous blood samples. Bland-Altman analysis compared measured and calculated arterial values of pH, PCO2, and PO2. Subgroup analyses were performed for normal, chronic hypercapnia and chronic base excess, acute hyper- and hypocapnia, and acute and chronic base deficits.Results: 811 samples from 12 studies were included. Bias and limits of agreement for measured and calculated values: pH 0.001 (-0.029 to 0.031), PCO2 -0.08 (-0.65 to 0.49) kPa, and PO2 0.04 (-1.71 to 1.78) kPa, with similar values for all sub-group analyses.Conclusion: These data suggest that v-TAC analysis may have a role in replacing ABGs, avoiding arterial puncture. Substantial data exist in patients with chronic hypercapnia and chronic base excess, acute hyper- and hypocapnia, and in patients with relatively normal acid-base status, with similar bias and precision across groups and across study data. Limited data exist for patients with acute and chronic base deficits.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"553-559"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 2 severe asthma: pathophysiology and treatment with biologics. 2 型重症哮喘：病理生理学和生物制剂治疗。

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-07-23 DOI: 10.1080/17476348.2024.2380072

Corrado Pelaia, James Melhorn, Timothy Sc Hinks, Simon Couillard, Alessandro Vatrella, Girolamo Pelaia, Ian D Pavord

{"title":"Type 2 severe asthma: pathophysiology and treatment with biologics.","authors":"Corrado Pelaia, James Melhorn, Timothy Sc Hinks, Simon Couillard, Alessandro Vatrella, Girolamo Pelaia, Ian D Pavord","doi":"10.1080/17476348.2024.2380072","DOIUrl":"10.1080/17476348.2024.2380072","url":null,"abstract":"Introduction: The hallmark of most patients with severe asthma is type 2 inflammation, driven by innate and adaptive immune responses leading to either allergic or non-allergic eosinophilic infiltration of airways. The cellular and molecular pathways underlying severe type 2 asthma can be successfully targeted by specific monoclonal antibodies.Areas covered: This review article provides a concise overview of the pathophysiology of type 2 asthma, followed by an updated appraisal of the mechanisms of action and therapeutic efficacy of currently available biologic treatments used for management of severe type 2 asthma. Therefore, all reported information arises from a wide literature search performed on PubMed.Expert opinion: The main result of the recent advances in the field of anti-asthma biologic therapies is the implementation of a personalized medicine approach, aimed to achieve clinical remission of severe asthma. Today this accomplishment is made possible by the right choice of the most beneficial biologic drug for the pathologic traits characterizing each patient, including type 2 severe asthma and its comorbidities.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"485-498"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current technological advancement in asthma care. 当前哮喘护理技术的进步。

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-07-17 DOI: 10.1080/17476348.2024.2380067

Ali Hakizimana, Pooja Devani, Erol A Gaillard

{"title":"Current technological advancement in asthma care.","authors":"Ali Hakizimana, Pooja Devani, Erol A Gaillard","doi":"10.1080/17476348.2024.2380067","DOIUrl":"10.1080/17476348.2024.2380067","url":null,"abstract":"Introduction: Asthma is a common chronic respiratory disease affecting 262 million people globally, causing half a million deaths each year. Poor asthma outcomes are frequently due to non-adherence to medication, poor engagement with asthma services, and a lack of objective diagnostic tests. In recent years, technologies have been developed to improve diagnosis, monitoring, and care.Areas covered: Technology has impacted asthma care with the potential to improve patient outcomes, reduce healthcare costs, and provide personalized management. We focus on current evidence on home diagnostics and monitoring, remote asthma reviews, and digital smart inhalers. PubMed, Ovid/Embase, Cochrane Library, Scopus and Google Scholar were searched in November 2023 with no limit by year of publication.Expert opinion: Advanced diagnostic technologies have enabled early asthma detection and personalized treatment plans. Mobile applications and digital therapeutics empower patients to manage their condition and improve adherence to treatments. Telemedicine platforms and remote monitoring devices have the potential to streamline asthma care. AI algorithms can analyze patient data and predict exacerbations in proof-of-concept studies. Technology can potentially provide precision medicine to a wider patient group in the future, but further development is essential for implementation into routine care which in itself will be a major challenge.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"499-512"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic obstructive pulmonary disease and obstructive sleep apnea overlap: who to treat and how? 慢性阻塞性肺病和阻塞性睡眠呼吸暂停重叠：治疗对象和方法？

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-08-02 DOI: 10.1080/17476348.2024.2384036

Bernie Y Sunwoo, Janna R Raphelson, Atul Malhotra

{"title":"Chronic obstructive pulmonary disease and obstructive sleep apnea overlap: who to treat and how?","authors":"Bernie Y Sunwoo, Janna R Raphelson, Atul Malhotra","doi":"10.1080/17476348.2024.2384036","DOIUrl":"10.1080/17476348.2024.2384036","url":null,"abstract":"Introduction: The co-existence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), or the overlap syndrome, is common and associated with a distinct pattern of nocturnal hypoxemia and worse clinical outcomes than either disease alone. Consequently, identifying who and how to treat these patients is essential.Areas covered: Treatment is recommended in all patients with OSA and symptoms or systemic hypertension, but determining symptoms attributable to OSA can be challenging in patients with COPD. Treatment should be considered in asymptomatic patients with moderate to severe OSA and COPD with pulmonary hypertension and comorbid cardiovascular and cerebrovascular disease, especially if marked hypoxic burden. CPAP is effective, but in patients with the overlap syndrome and daytime hypercapnia, high-intensity noninvasive ventilation aiming to lower PaCO2 may have additional benefits. Additionally, in those with severe resting daytime hypoxemia, supplemental oxygen improves survival and should be added to positive airway pressure. The role of alternative non-positive airway pressure therapies in the overlap syndrome needs further study.Expert opinion: Both COPD and OSA are heterogeneous disorders with a wide range of disease severity and further research is needed to better characterize and prognosticate patients with the overlap syndrome to personalize treatment.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"527-537"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality of patients with COPD. 慢性阻塞性肺病患者的死亡率。

Expert review of respiratory medicine Pub Date : 2024-06-01 Epub Date: 2024-07-30 DOI: 10.1080/17476348.2024.2375416

David M G Halpin

{"title":"Mortality of patients with COPD.","authors":"David M G Halpin","doi":"10.1080/17476348.2024.2375416","DOIUrl":"10.1080/17476348.2024.2375416","url":null,"abstract":"Introduction: Chronic obstructive pulmonary disease (COPD) is the third most common cause of death worldwide and 24% of the patients die within 5 years of diagnosis.Areas covered: The epidemiology of mortality and the interventions that reduce it are reviewed. The increasing global deaths reflect increases in population sizes, increasing life expectancy and reductions in other causes of death. Strategies to reduce mortality aim to prevent the development of COPD and improve the survival of individuals. Historic changes in mortality give insights: improvements in living conditions and nutrition, and later improvements in air quality led to a large fall in mortality in the early 20th century. The smoking epidemic temporarily reversed this trend.Older age, worse lung function and exacerbations are risk factors for death. Single inhaler triple therapy; smoking cessation; pulmonary rehabilitation; oxygen therapy; noninvasive ventilation; and surgery reduce mortality in selected patients.Expert opinion: The importance of addressing the global burden of mortality from COPD must be recognized. Steps must be taken to reduce it, by reducing exposure to risk factors, assessing individual patients' risk of death and using treatments that reduce the risk of death. Mortality rates are falling in countries that have adopted a comprehensive approach to COPD prevention and treatment.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"381-395"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sleep disordered breathing: OSA-COPD overlap. 睡眠呼吸障碍：OSA-COPD 重叠。

Expert review of respiratory medicine Pub Date : 2024-06-01 Epub Date: 2024-07-02 DOI: 10.1080/17476348.2024.2373790

Mafalda van Zeller, Walter T McNicholas

{"title":"Sleep disordered breathing: OSA-COPD overlap.","authors":"Mafalda van Zeller, Walter T McNicholas","doi":"10.1080/17476348.2024.2373790","DOIUrl":"10.1080/17476348.2024.2373790","url":null,"abstract":"Introduction: Sleep has important effects on breathing and gas exchange that may have negative consequences in patients with chronic obstructive pulmonary disease (COPD). COPD and obstructive sleep apnea (OSA) are highly prevalent and may coexist, which is referred to as the overlap syndrome.Areas covered: The probability of OSA-COPD overlap represents the balance of protective and promoting factors such as hyperinflation and fluid retention; thus, different clinical COPD phenotypes influence the likelihood of comorbid OSA. The clinical presentation of OSA-COPD overlap is nonspecific, and the diagnosis requires clinical awareness to identify patients needing overnight studies. Both COPD and OSA are associated with a range of overlapping physiological and biological disturbances including hypoxia and inflammation that contribute to cardiovascular comorbidities. The management of OSA-COPD overlap patients differs from those with COPD alone and the survival of overlap patients treated with positive airway pressure (PAP) is superior to those untreated.Expert opinion: The recognition of OSA-COPD overlap has important clinical relevance because of its impact on outcomes and management. Management of the overlap should address both sleep quality and disordered gas exchange. PAP therapy has demonstrated reductions in COPD exacerbations, hospitalizations, healthcare costs and mortality in overlap patients.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"369-379"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is pre-COPD and do we know how to treat it? 什么是慢性阻塞性肺病前期，我们知道如何治疗吗？

Expert review of respiratory medicine Pub Date : 2024-06-01 Epub Date: 2024-07-03 DOI: 10.1080/17476348.2024.2375418

Davor Plavec, Žarko Vrbica

{"title":"What is pre-COPD and do we know how to treat it?","authors":"Davor Plavec, Žarko Vrbica","doi":"10.1080/17476348.2024.2375418","DOIUrl":"10.1080/17476348.2024.2375418","url":null,"abstract":"Introduction: Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of morbidity and mortality worldwide. The lung damage in COPD is associated with an enhanced chronic inflammatory response in the airways and lung tissue to harmful particles or gases. Early detection and treatment of COPD can help manage symptoms and slow the progression of the disease.Areas covered: Status of knowledge regarding early diagnosis, definition of pre-COPD, possible new tools for early diagnosis, possibilities of early treatment, and the results of studies in this population are discussed. Literature search (2014-2024) was done in PubMed, EMBASE, and WoS databases using the keywords COPD, early diagnosis, treatment, smoking, prevention; with additional search of literature in found articles.Expert opinion: No early case-finding programs have been proposed or validated, so we still have many patients diagnosed in the late stage of the disease. Clinically manifest COPD is characterized as typically progressive and irreversible with current therapeutic options. If we aim to reduce the mortality and morbidity from COPD we should target these steps: Prevention; Early diagnosis; Form registries of persons at risk for COPD development; Diagnose preclinical COPD; and discover new preventive therapeutic interventions.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"349-354"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the diagnosis and follow-up of pleural lesions: a scoping review. 胸膜病变诊断和随访的进展：范围综述。

Expert review of respiratory medicine Pub Date : 2024-06-01 Epub Date: 2024-07-19 DOI: 10.1080/17476348.2024.2375421

Vasiliki Panou, Rahul Bhatnagar, Najib Rahman, Thomas Decker Christensen, Pia Iben Pietersen, Arman Arshad, Christian B Laursen

{"title":"Advances in the diagnosis and follow-up of pleural lesions: a scoping review.","authors":"Vasiliki Panou, Rahul Bhatnagar, Najib Rahman, Thomas Decker Christensen, Pia Iben Pietersen, Arman Arshad, Christian B Laursen","doi":"10.1080/17476348.2024.2375421","DOIUrl":"10.1080/17476348.2024.2375421","url":null,"abstract":"Introduction: Pleural lesions may have heterogeneous presentation and causes. In recent years, there have been significant advances in pleural lesions diagnostics. The aim of this review is to provide an overview of the state-of-the-art, and recent updates for diagnostic modalities and monitoring regimes for pleural lesions.Areas covered: A literature search was conducted through PubMed and Web of Science for relevant articles published from 1 January 2000- 1 March 2023. This article critically appraises the radiological modalities and biopsy techniques that are employed in pleural lesions diagnostics, including chest radiography, thoracic ultrasound, computed tomography, F-fluorodeoxyglycose positron emission tomography, magnetic resonance imaging, percutaneous, and thoracoscopic pleural biopsies with reference to their strengths, limitations, and clinical use. The review asserts also the available literature regarding monitoring algorithms.Expert opinion: Despite the recent advances in the field, there are several key areas for improvement, including the development and validation of minimal invasive methods and tools for risk stratification, the integration of multi-omics technologies, the implementation of standardized, evidence-based diagnostic and monitoring guidelines and increased focus on research and patient-centric approaches. The broad establishment of dedicated pleural clinics may significantly assist toward this direction.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"423-434"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0